To achieve its objective of making diagnostics simple to use, inexpensive, disposable, and environmentally friendly, Sherlock Biosciences purchased Sense Biodetection in February 2023. Products for SDA-based diagnostics are offered by Sense Biodetection.
The FDA received an emergency use authorization request from Lucira Health, Inc. in January 2023 for the OTC use of their straightforward, at-home molecular COVID-19 and flu test, which makes use of SDA technology.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5259
Published Date: Sep 25, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The growing prevalence of infectious diseases and increasing awareness about the benefits of strand displacement amplification are some of the major factors anticipated to drive the growth of the strand displacement amplification market.
The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024 â€“ 2036.
The major players in the market are Sherlock Biosciences, Lucigen Corporation, Bio-Rad Laboratories Inc., G-Biosciences, New England Bio-Labs, Geno Technologies Inc., and others.
The diagnostic laboratories segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.